Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference43 articles.
1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN;Ferlay;Int. J. Cancer,2012
2. EGFR tyrosine kinase inhibitors in lung Cancer: an evolving story;Lecia;Annu. Rev. Med.,2008
3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N. Engl. J. Med.,2004
4. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N. Engl. J. Med.,2013
5. Comprehensive molecular profiling of lung adenocarcinoma;Cancer Genome Atlas Research N;Nature,2014
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: Testing Considerations and Clinical Outcomes a 3 years screening experience;2024-08-11
2. Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy;Journal of Medicinal Chemistry;2024-08-01
3. MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations;Translational Lung Cancer Research;2024-04
4. RET splice site variants in medullary thyroid carcinoma;Frontiers in Genetics;2024-03-19
5. MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature;Therapeutic Advances in Medical Oncology;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3